When combining results from all published surveys, about one in nine global study participants (10.7%) reported ever using preexposure prophylaxis (PrEP) by 2017, a significant increase since US FDA approval in 2012 [odds ratio (OR) = 1.6/year, P < 0.00001]. Moreover, nearly one in six US-based study participants (17.3%) and nearly one in four MSM who met the Centers for Disease Control and Prevention's PrEP indications (24.5%) reported ever using PrEP by 2016. The odds of reporting PrEP use are approximately doubling each year (OR = 1.8/year, P < 0.00001; OR = 2.0/year, P < 0.00001).
aPrevention Research Branch, Division of HIV/AIDS Prevention, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia
bORISE Fellow, Oak Ridge Institute for Science and Education, U.S. Department of Energy, Oak Ridge, Tennessee
cICF International Inc, Atlanta, Georgia
dSan Francisco AIDS Foundation, San Francisco, California, USA.
Correspondence to Emiko Kamitani, PhD, RN, The U.S. Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, Prevention Research Branch, 1600 Clifton Rd., Mailstop E-37, Atlanta, GA 30333, USA. Tel: +1 404 639 8228; fax: +1 404 639 1950; e-mail: firstname.lastname@example.org
Received 23 February, 2018
Accepted 8 July, 2018
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).